Pontifax Management 4 G.P. (2015) Ltd. — SEC Form 4 filings

SEC reporting owner CIK 1726334. 2 Form 4 filings on record with FilingPulse; latest filed 2025-10-17.

Transaction summary — filings shown

Covers all 2 filings on record, filed 2025-09-16 to 2025-10-17. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
Keros Therapeutics, Inc. (KROS)10% owner14 legs · 4,787,331 sh · $84,975,125
LB PHARMACEUTICALS INC (LBRX)10% owner11 leg · 1,000,000 sh · $15,000,0002

Form 4 filings — Pontifax Management 4 G.P. (2015) Ltd.

FiledFormIssuerReported transactionsSource
2025-10-174Keros Therapeutics, Inc. (KROS)
jointly with Pontifax (Israel) IV, L.P., Pontifax (Cayman) IV L.P., Pontifax (China) IV L.P., Pontifax Late Stage Fund L.P., Pontifax Late Stage GP Ltd., Kariv Tomer, Nussbaum Ran
Sale (S): 2,284,612 @ $17.75 · Sale (S): 1,121,045 @ $17.75 · Sale (S): 1,226,412 @ $17.75 · Sale (S): 155,262 @ $17.75EDGAR
2025-09-164LB PHARMACEUTICALS INC (LBRX)Conversion (C): 411,681 · Purchase (P): 1,000,000 @ $15 · Conversion (C): 10,000,000 (derivative)EDGAR

FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1726334 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →